Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer (RAINFOL™-07)

2. november 2026 oppdatert av: Genmab

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

This Phase 3 study will be conducted in different countries around the world with up to about 688 participants.

The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab.

Participants will receive either:

  • Rina-S monotherapy (by itself),
  • Rina-S plus bevacizumab,
  • investigator's choice chemotherapy (by itself) (standard of care), or
  • investigator's choice chemotherapy plus bevacizumab (standard of care).

No participants will be given placebo. Participants will participate in 1 of 2 arms.

The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 or 4 weeks, depending on medication received). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective.

The overall study duration (including screening, treatment, and follow-up) will be different for every participant.

Studieoversikt

Detaljert beskrivelse

This is a global, open-label, randomized, Phase 3 study of Rina-S ± bevacizumab versus investigator's choice (IC) ± bevacizumab as second-line (2L) treatment in participants with recurrent platinum-sensitive ovarian cancer (PSOC).

Studietype

Intervensjonell

Registrering (Antatt)

688

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Pirkanmaa
      • Tampere, Pirkanmaa, Finland, 33520
        • Rekruttering
        • Tampere University Hospital
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope
    • Connecticut
      • Danbury, Connecticut, Forente stater, 06810
        • Rekruttering
        • Danbury Hospital
    • Oregon
      • Tigard, Oregon, Forente stater, 97223
        • Rekruttering
        • Compass Oncology - West Cancer Center (Northwest Cancer Specialists, P.C.)
    • Pennsylvania
      • Bensalem, Pennsylvania, Forente stater, 19020
        • Rekruttering
        • Alliance Cancer Specialists, PC
    • Utah
      • South Jordan, Utah, Forente stater, 84095
        • Rekruttering
        • Utah Cancer Specialists
    • West Virginia
      • Morgantown, West Virginia, Forente stater, 26506
        • Rekruttering
        • West Virginia University
    • Wisconsin
      • Waukesha, Wisconsin, Forente stater, 53188
        • Rekruttering
        • ProHealth Care Inc
    • Koto City
      • Tokyo, Koto City, Japan, 135-8550
        • Rekruttering
        • The Cancer Institute Hospital of JFCR
    • Niigata
      • Chuo Ku Niigata, Niigata, Japan, 951-8566
        • Rekruttering
        • Niigata Cancer Center Hospital
    • Tokushima
      • Tokushima, Tokushima, Japan, 770-8503
        • Rekruttering
        • Tokushima University Hospital
    • Yamagata
      • Yamagata, Yamagata, Japan, 990-9585
        • Rekruttering
        • Yamagata University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Key Inclusion Criteria:

  • Participant must have histologically confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), including primary peritoneal or fallopian tube cancer.
  • Participant must have documented recurrence or progression after first-line (1L) platinum-based chemotherapy regimen (carboplatin + paclitaxel ≥ 4 cycles) with or without bevacizumab and have platinum-sensitive disease defined as radiographic progression at least 6 months (ie, >183 days) after their last dose administration of platinum-based therapy.
  • Prior poly (ADP-ribose) polymerase inhibitor(s) (PARPi) maintenance therapy (alone or in combination with bevacizumab) is required for participants with breast cancer susceptibility gene (BRCA 1- and BRCA 2)-mutated (germline or somatic) or homologous recombination deficiency (HRD)-positive disease.
  • Participants must have measurable disease per RECIST v1.1 by investigator at baseline.
  • All participants must provide a tumor specimen.
  • Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at baseline.

Key Exclusion Criteria:

  • Participants with clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumors.
  • Participant has received previous therapy with other anti-angiogenetic agents different from bevacizumab or biosimilar.
  • Participant has received prior therapy with an antibody-drug conjugate (ADC) containing a topoisomerase-1 inhibitor.
  • Participant has received prior therapy with an ADC targeting folate receptor alpha (FRα).

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm 1: Rina-S ± Bevacizumab

Participants will receive Rina-S ± bevacizumab once every 3 weeks (Q3W).

IV infusion

Intravenous (IV) infusion

Andre navn:
  • PRO1184
  • Rinatabart Sesutecan
  • GEN1184
Aktiv komparator: Arm 2: Investigator Choice of Chemotherapy ± Bevacizumab

Participants will receive carboplatin plus gemcitabine ± bevacizumab, carboplatin plus paclitaxel ± bevacizumab, or carboplatin plus pegylated liposomal doxorubicin (PLD) ± bevacizumab.

IV infusion

IV infusion

IV infusion

IV infusion

IV infusion

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)
Tidsramme: Up to approximately 3 years
Up to approximately 3 years

Sekundære resultatmål

Resultatmål
Tidsramme
Total overlevelse (OS)
Tidsramme: Opptil ca 5 år
Opptil ca 5 år
Varighet av respons (DOR) per RECIST v1.1
Tidsramme: Opptil ca 3 år
Opptil ca 3 år
Antall deltakere med bivirkninger av behandlingsopplevelse (TEAES)
Tidsramme: Opptil omtrent 3 år
Opptil omtrent 3 år
PFS per RECIST v1.1, as Determined by Investigator
Tidsramme: Up to approximately 3 years
Up to approximately 3 years
Objective Response Rate (ORR) per RECIST v1.1
Tidsramme: Up to approximately 3 years
Up to approximately 3 years
Progression-free Survival on the Next Line of Therapy After the First Progression (PFS2)
Tidsramme: Up to approximately 3 years
Up to approximately 3 years
Time to First Subsequent Therapy (TFST)
Tidsramme: Up to approximately 3 years
Up to approximately 3 years
Cancer Antigen 125 (CA-125) Response per Gynecologic Cancer Intergroup (GCIG) Criteria
Tidsramme: Up to approximately 3 years
Up to approximately 3 years
Overall Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Score Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)
Tidsramme: Baseline up to approximately 3 years
Baseline up to approximately 3 years
Time to Deterioration (TTD) in the GHS/QoL Score Using the EORTC QLQ C30 Questionnaire
Tidsramme: Up to approximately 3 years
Up to approximately 3 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Study Official, Genmab

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

28. august 2026

Primær fullføring (Antatt)

1. desember 2029

Studiet fullført (Antatt)

1. november 2031

Datoer for studieregistrering

Først innsendt

27. april 2026

Først innsendt som oppfylte QC-kriteriene

27. april 2026

Først lagt ut (Faktiske)

4. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere